Products

MedNova: source-traced IND gap assessment.

MedNova is Amia’s regulatory AI product. It reads an IND package against guidance and flags missing, inconsistent and unsupported content before submission, for expert review.

MedNova demonstration workspace showing IND gap findings for a hypothetical sterile injectable, using demo data
Demonstration workspace with a hypothetical IND and demo data.

What MedNova does

A second reader that shows its evidence.

  • Deterministic checks. A rules engine applies checks that are repeatable, kept separate from AI reasoning.
  • Severity-ranked findings. Critical, major and minor findings, each with the evidence and source attached.
  • Source tracing. Findings link back to the passage in your documents or the public source.
  • Expert review. In Amia service engagements, a regulatory expert reviews findings before they reach you.
  • Deployment options. Deployment in your own cloud environment or on premise can be arranged.
MedNova is a product. Amia.ai’s consulting and engineering services are separate and are not limited to MedNova. A full-IND extension is in development.

MedNova supports regulatory work and is not a substitute for regulatory review. It does not guarantee regulatory approval.

Start a conversation

Want to see MedNova on a sample IND?

We run guided demonstrations with demo data. Tell us about your program and timeline.